Skip to content

Research on the median effective concentration of sevoflurane in caesarean sections under Narcotrend monitoring

Research on the median effective concentration of sevoflurane in caesarean sections under Narcotrend monitoring

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034512
Enrollment
Unknown
Registered
2020-07-07
Start date
2019-01-01
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean section under general anesthesia

Interventions

Group A:Remifentanil 0.05ug.kg-1.min-1

Sponsors

Quanzhou Women's and Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) Aged >=18 years; (2) Hospitalized patients undergoing cesarean section during elective delivery of single term pregnancy; (3) The American society of anesthesiologists (ASA) class I~ II; (4) Subjects participate voluntarily and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Suffering from serious diseases of the heart, lung, liver, kidney or other organs, hemorrhagic diseases or other systemic diseases; (2) Potentially difficult airway (modified Mallampati IV or known pathological changes of upper respiratory tract or neck); (3) Patients with gastroesophageal reflux disease; (4) Intrauterine restriction or fetal damage; (5) Persons with BMI >= 35 kg/m2; (6) Patients with language disorders, psychological disorders, cognitive dysfunction or neuromuscular diseases; (7) Allergic to the drugs to be used; (8) Alcoholism or drug abuse; (9) Patients with myasthenia gravis or bronchial asthma; (10) Patients with diabetes, hypertension and hypotension.

Design outcomes

Primary

MeasureTime frame
MAC of sevoflurane;Narcotrend EEG index;

Secondary

MeasureTime frame
Apgar;

Countries

China

Contacts

Public ContactLian Jianfeng

Quanzhou Women's and Children's Hospital

89329996@QQ.COM+86 13505027033

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026